PA8778601A1 - Inhibidores de la unión entre hdm2 y el proteasoma - Google Patents
Inhibidores de la unión entre hdm2 y el proteasomaInfo
- Publication number
- PA8778601A1 PA8778601A1 PA20088778601A PA8778601A PA8778601A1 PA 8778601 A1 PA8778601 A1 PA 8778601A1 PA 20088778601 A PA20088778601 A PA 20088778601A PA 8778601 A PA8778601 A PA 8778601A PA 8778601 A1 PA8778601 A1 PA 8778601A1
- Authority
- PA
- Panama
- Prior art keywords
- proteasoma
- hdm2
- union
- inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
ESTA INVENCION PROPORCIONA METODOS PARA DETERMINAR SI UN COMPUESTO DE ENSAYO INTERACTUA CON LA UNION ENTRE HDM2 Y EL PROTEASOMA. PROPORCIONA ADEMAS COMPUESTOS, COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHO COMPUESTO DE ENSAYO, Y EL USO DE DICHOS COMPUESTOS Y COMPOSICIONES, EN PARTICULAR COMO AGENTE ANTICANCERIGENO, AUN MAS PARTICULAR PARA TRATAR TRATORNOS PROLIFERATIVOS CELULARES EN UN SUJETO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07107042 | 2007-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8778601A1 true PA8778601A1 (es) | 2008-11-19 |
Family
ID=38564545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20088778601A PA8778601A1 (es) | 2007-04-26 | 2008-04-24 | Inhibidores de la unión entre hdm2 y el proteasoma |
Country Status (10)
Country | Link |
---|---|
US (1) | US20100129933A1 (es) |
EP (1) | EP2140019A1 (es) |
JP (1) | JP2010529418A (es) |
CN (1) | CN101790583A (es) |
AR (1) | AR066149A1 (es) |
CA (1) | CA2683071A1 (es) |
CL (1) | CL2008001213A1 (es) |
PA (1) | PA8778601A1 (es) |
TW (1) | TW200912000A (es) |
WO (2) | WO2008132155A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
KR101730407B1 (ko) * | 2009-02-04 | 2017-04-26 | 얀센 파마슈티카 엔.브이. | 항암제로서의 인돌 유도체 |
US8580803B2 (en) | 2009-12-30 | 2013-11-12 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
EP3102576B8 (en) | 2014-02-03 | 2019-06-19 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
PT3207043T (pt) | 2014-10-14 | 2019-03-25 | Vitae Pharmaceuticals Llc | Inibidores de di-hidropirrolopiridina de ror-gama |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
MX2018001073A (es) | 2015-08-06 | 2018-06-12 | Chimerix Inc | Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales. |
WO2017079723A1 (en) * | 2015-11-07 | 2017-05-11 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
MX2019002212A (es) | 2016-08-24 | 2019-07-08 | Arqule Inc | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
AU2018307919B2 (en) | 2017-07-24 | 2022-12-01 | Vitae Pharmaceuticals, Llc | Inhibitors of RORϒ |
EP3684771A1 (en) | 2017-09-21 | 2020-07-29 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
AU7127296A (en) * | 1995-09-18 | 1997-04-09 | Novartis Ag | Assay for identifying inhibitors of the interaction between proteins p53 and dm2 |
US20020045192A1 (en) * | 2001-09-19 | 2002-04-18 | St. Jude Children's Research Hospital | Arf and HDM2 interaction domains and methods of use thereof |
WO2005021782A1 (en) * | 2003-08-29 | 2005-03-10 | California Institute Of Technology | Methods of identifying modulators of proteasome activity |
NZ553646A (en) * | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
US9051572B2 (en) * | 2005-01-20 | 2015-06-09 | Ryboquin Company Limited | Modulators of Itch ubiquitinase activity |
-
2007
- 2007-04-26 US US12/597,356 patent/US20100129933A1/en not_active Abandoned
-
2008
- 2008-04-24 PA PA20088778601A patent/PA8778601A1/es unknown
- 2008-04-25 CL CL2008001213A patent/CL2008001213A1/es unknown
- 2008-04-25 JP JP2010504714A patent/JP2010529418A/ja not_active Withdrawn
- 2008-04-25 CN CN200880022295A patent/CN101790583A/zh active Pending
- 2008-04-25 WO PCT/EP2008/055051 patent/WO2008132155A2/en active Application Filing
- 2008-04-25 TW TW097115161A patent/TW200912000A/zh unknown
- 2008-04-25 AR ARP080101769A patent/AR066149A1/es unknown
- 2008-04-25 WO PCT/EP2008/055088 patent/WO2008132175A1/en active Application Filing
- 2008-04-25 EP EP08736586A patent/EP2140019A1/en not_active Withdrawn
- 2008-04-25 CA CA002683071A patent/CA2683071A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2008132155A2 (en) | 2008-11-06 |
TW200912000A (en) | 2009-03-16 |
CL2008001213A1 (es) | 2008-11-03 |
US20100129933A1 (en) | 2010-05-27 |
WO2008132155A3 (en) | 2009-03-26 |
CN101790583A (zh) | 2010-07-28 |
JP2010529418A (ja) | 2010-08-26 |
AR066149A1 (es) | 2009-07-29 |
WO2008132175A1 (en) | 2008-11-06 |
EP2140019A1 (en) | 2010-01-06 |
CA2683071A1 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8778601A1 (es) | Inhibidores de la unión entre hdm2 y el proteasoma | |
CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
GT200900201A (es) | Formulaciones para el tratamiento del cáncer. | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CO6450665A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
CL2009000260A1 (es) | Antagonista de pcsk9 que comprende un dominio cdr3 de la region variable de la cadena liviana y pesada, el cual inhibe la captacion celular del ldl, composicion farmaceutica que comprende dicho antagonista, uso de este, secuencia nucleotidica que codifica el antagonista, vector y celula huesped que la comprende. | |
CR11427A (es) | 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
SV2009003307A (es) | Quinazolinas para la inhibicion de pdk1 | |
CR10444A (es) | Anticuerpo humanizado de c-kit | |
CR8929A (es) | Polimorfo ii de rapamicina y usos del mismo | |
CR11216A (es) | Anticuerpos anti-cd79b e inmmunoconjugados y metodos de uso de los mismos | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2011001232A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer | |
CL2011000603A1 (es) | Uso de compuestos de ditiina-tetracarboximidas que sirven para combatir hongos fitopatogenos; procedimiento para combatir dichos hongos; compuestos de ditiina-tetracarboximidas; uso de compuestos de ditiina-diisoimidas; y compuestos ditiina-diisoimidas. | |
UY32659A (es) | Pirazinilpirazoles | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
ECSP088543A (es) | Anticuerpos anti-ox40l y métodos que los utilizan | |
GT200900124A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
SV2010003559A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
GT201000047A (es) | Mejoras en compuestos organicos o relacionadas con los mismos |